State of the Russian Oncology Service: malignant neoplasms of the tongue C01, 02 (mortality rate in patients, median survival of patients, taking into account the stage of the disease and the histological structure of the tumor). Part II

2021 ◽  
Author(s):  
Vakhtang M. Merabishvili ◽  
Elvira N. Merabishvili ◽  
Alexander M. Shcherbakov ◽  
Alexander B. Vasiliev ◽  
Alexey F. Barsukov ◽  
...  
Keyword(s):  
Survival Rate ◽  
Mortality Rate ◽  
Cancer Patients ◽  
Median Survival ◽  
Tongue Cancer ◽  
Survival Rates ◽  
Relative Survival ◽  
Population Based ◽  
Malignant Neoplasms ◽  
Oncology Service

Malignant neoplasms of the tongue occupy 0.55% in the general structure of the cancer incidence in Russian population. No information on other parameters (the number of deaths, mortality of patients, their distribution by stages of the disease and other analytical indicators) is provided in the official reporting. The opportunity appeared only with the development of Population-based Cancer Registries (PCR) system, but this wealth of material is not used for the official reporting. Tongue cancer is a visual localization with a high mortality rate, which requires special attention. The study was conducted to investigate the state of Russian Oncology Service for tongue cancer patients with the calculations of one-year mortality rate, annual mortality rate, median survival, 1,3,5-year observed and relative survival rates, first time in Russia, at the level of the newly created Population-based Cancer Registry of the Federal District. In Russia, there has been little research on the analysis of the cancer survival rate at the population level. We have been conducting developments for all malignant tumors localizations since 2000 based on the St. Petersburg PCR database. The level of 5-year observed and relative survival rates for tongue cancer patients in Russia (St. Petersburg and the NWFD RF) has been found to be significantly lower than the EU average (Eurocare-4). To carry out this study, 5188 observations from the NWFD RF PCR database were selected. It has been established that during 4 periods of observation, the mortality rate for tongue cancer patients during the first year of observation in the NWFD RF has decreased under the C01 rubric (cancer of the base of the tongue) from 58.5 to 45.8%; and under the C02 rubric (malignant neoplasm of other and unspecified parts of tongue) from 54.5 to 42.7%. The five-year survival rate for tongue cancer patients has increased by 23.3%.

scholarly journals Improvement of Survival over Time for Colorectal Cancer Patients: A Population-Based Study

2020 ◽  
Vol 9 (12) ◽  
pp. 4038
Author(s):  
Audrius Dulskas ◽  
Vytautas Gaizauskas ◽  
Inga Kildusiene ◽  
Narimantas Evaldas Samalavicius ◽  
Giedre Smailyte
Keyword(s):  
Colorectal Cancer ◽  
Survival Rate ◽  
Cancer Patients ◽  
Survival Rates ◽  
Relative Survival ◽  
Population Based ◽  
Colorectal Cancers ◽  
Advanced Cancer Patients ◽  
Regional Metastases ◽  
Colorectal Cancer Patients

Purpose: In this study, we analyzed the mortality and survival of colorectal cancer patients in Lithuania. Methods: This was a national cohort study. Population-based data from the Lithuanian Cancer Registry and period analyses were collected. Overall, 20,980 colorectal cancer patients were included. We examined the changes in colorectal cancer mortality and survival rates between 1998 and 2012 according to cancer anatomical sub-sites and stages. We calculated the 5-year relative survival estimates using period analysis. Results: Overall, 20,980 colorectal cancer cases reported from 1998 to 2012 were included in the study. The total number of newly diagnosed colorectal cancers increased from 1998–2002 to 2008–2012 by 12.1%. The highest number of colorectal cancers was localized and increased from 33.9% to 42.0%. The number of cancers with regional metastases and advanced cancers decreased by 11.1% and 15.5%, respectively. An increased number of new cases was observed for almost all colon cancer sub-sites. The overall 5-year relative survival rate increased from 37.9% in 1998–2002 to 51.5% in 2008–2012. We showed an increase in survival rates for all stages and all sub-sites. In the most recent period, patients with a localized disease had a 5-year survival rate of 78.6%, while survival estimates for advanced cancer patients remained low at 6.6%. Conclusion: Although survival rates variated in colorectal cancer patients according to disease stages and sub-sites, we showed increased survival rates for all patients.

scholarly journals Analysis of Mortality and Survival Rate of Liver Cancer in Zhejiang Province in China: A General Population-Based Study

2019 ◽  
Vol 2019 ◽  
pp. 1-6
Author(s):  
Fang-Rong Fei ◽  
Ru-Ying Hu ◽  
Wei-Wei Gong ◽  
Jin Pan ◽  
Meng Wang
Keyword(s):  
Survival Rate ◽  
Mortality Rate ◽  
Liver Cancer ◽  
Cancer Patients ◽  
Rural Areas ◽  
Urban Areas ◽  
Survival Rates ◽  
Relative Survival ◽  
Zhejiang Province ◽  
World Population

Background. Few accurate up-to-date studies provide liver cancer mortality and survival information in Zhejiang province. This research aimed to depict the mortality and survival of liver cancer in Zhejiang province in China during 2005-2010. Methods. The data were collected from the Zhejiang Chronic Disease Surveillance Information and Management System, and the mortality rates of liver cancer were calculated by gender, age, and areas. Chinese population census in 2000 and Segi’s world population were used for age-standardized mortality rate. The observed and relative survival rates of liver cancer patients were analyzed. Results. The crude mortality rate of liver cancer was 32.11/105. The age-standardized mortality rate was 17.39/105 and 23.07/105 by Chinese population (ASIRC) and Segi’s world population (ASIRW), respectively. The crude liver cancer mortality rate and age-standardized rate in urban areas were lower than those of rural areas. The overall 1-, 3-, and 5-year observed survival (OS) rates of liver cancer patients were 38.61%, 21.65%, and 16.83%, respectively. The 1-, 3-, and 5-year relative survival (RS) rates of liver cancer patients were 39.49%, 23.27%, and 19.09%, respectively. Survival rate decreased obviously within 1 to 5 years and then leveled off. It was shown that the male overall survival rate was higher than the female one and the difference was statistically significant (P<0.05). Conclusions. Both lower mortality and better survival rates were observed in urban areas, compared to rural areas. Relevant parties including government, public resource, and propaganda department should devote enough attention to rural areas.

scholarly journals Period Analysis of Intraracial Differences in Incidence and Survival Rates in Epithelial Ovarian Cancer

2021 ◽  
Vol 2021 ◽  
pp. 1-10
Author(s):  
Lili Han ◽  
Sulaiya Husaiyin ◽  
Jing Liu ◽  
Miherinisha Maimaiti ◽  
Mayinuer Niyazi ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Survival Rate ◽  
Epithelial Ovarian Cancer ◽  
Median Survival ◽  
Survival Rates ◽  
Relative Survival ◽  
Population Based ◽  
Relative Survival Rate ◽  
Kaplan Meier ◽  
The Difference

Background. To explain the difference in the incidence and relative survival in a population-based cohort of women with epithelial ovarian cancer (EOC) postdiagnosis in the last forty years. EOC is the most common type of all ovarian cancers, but there is inadequate information about the variations related to long-term EOC survival. Methods. We acquired the incidence and relative survival rate data from the Surveillance, Epidemiology, and End Results (SEER) registries to analyze the epidemiological variations from 1974 to 2013 in EOC-affected individuals. The survival disparities in EOC-specific individuals due to age, race, and socioeconomic status (SES) were performed by Kaplan-Meier analysis. The Results. The overall incidence of EOC progressively declined to 9.0 per 100,000 from 11.4 in the last forty years. The median survival rate improved to 48 months in the first decade from a previous of 27 months in the fourth decade. The 5-year relative survival rate (RSR) increased to 44.3% that was previously 32.3% at the same time. However, between whites and blacks, an increase from 11 to 18 months was observed in the median survival differences. Between the low and high poverty groups, it was increased from 7 months to 12 months, respectively. Conclusions. The incidence rate of RSR and EOC-specific individuals in the last forty years was improved. However, the survival rates among different races and SES differed over time.

Studying Survival of Cancer Patients in Different Populations: Its Potential and Role

1997 ◽  
Vol 83 (1) ◽  
pp. 3-8 ◽  
Author(s):  
Andrea Micheli ◽  
Gemma Gatta ◽  
Arduino Verdecchia
Keyword(s):  
Cancer Patients ◽  
Health Expenditure ◽  
Cancer Survival ◽  
Relative Survival ◽  
Cancer Registries ◽  
Population Based ◽  
Malignant Neoplasms ◽  
Regional Health ◽  
Italian Regions ◽  
Different Populations

Rationale Survival figures from a population-based study incorporate the overall practice in diagnosis, cure and clinical follow-up for a specific disease within a given health care system. Being the outcome of a number of individual, social and economical aspects, population-based survival may be thought as index for measuring the level of a country's development. Data The EUROCARE project, a European Cancer Registries (CR) concerted action, provided reliable information on survival for more than 800,000 cancer patients from 11 European countries. A great deal of epidemiologic information has derived from EUROCARE. Women had a longer survival than men for all studied tumour sites, except for the colon. European survival variability was fairly high for several cancers, but it was lower for cancers with a relatively good prognosis and those sensitive to treatment. The ranking of populations of cancer survival tended to be fairly stable for many cancers: CR of Switzerland and Finland ranked high and Polish CR low. Denmark, Italian and France CR did not substantially differ from the European survival average. For most cancers, prognosis improved during the studied period (years of diagnosis: 1978–1985). Survival figures for colon (r = 0.74, males; r = 0.73, women) and female breast cancer (r = 0.57) well correlated with the national health expenditure of different participating countries. The ITACARE study, a new Italian Cancer Registries collaborative project involving more than 100,000 cancer patients, was set up to study survival differences within the country. Survival of cancer patients was not homogeneous in 7 studied Italian regions (the estimated 5-year relative survival for all malignant neoplasms combined ranked from 37.8% in CR of Sicily to 42.1% in those of Emilia-Romagna). The lowest levels of regional health expenditures were accompanied by the lowest levels of prognosis for overall cancers. However, a relatively low correlation among patient cancer survival and the regional health expenditure (r = 0.21) was found, suggesting that other factors such as different efficiency in managing cancer may play a role in explaining the intracountry differences. Conclusions Population-based survival figures may be used to study epidemiologic aspects, comparing different health systems, and may be interpreted as indexes for discussing inequalities in health in different populations.

Prostate cancer patient’s survival in Lithuania

2013 ◽  
Vol 19 (4) ◽  
pp. 439-444
Author(s):  
Giedrė Smailytė ◽  
Robertas Adomaitis ◽  
Karolis Ulinskas ◽  
Birutė Aleknavičienė
Keyword(s):  
Prostate Cancer ◽  
Survival Rate ◽  
Cancer Patients ◽  
Rural Areas ◽  
Survival Rates ◽  
Relative Survival ◽  
Care Quality ◽  
Place Of Residence ◽  
Icd 10 ◽  
Survival Differences

Background. The aim of this study was to evaluate changes in the survival of prostate cancer patients during the 12-year period and to analyze differences in survival by period of diagnosis, stage of disease, age and place of residence. Materials and methods. All newly diagnosed cases of prostate cancer (ICD-10, C61) in men were identified in the Lithuanian Cancer Registry for the period 1994–2005. Five-year relative survival estimates were computed with the Hakulinen method using the STATA software. Five-year relative survival estimates were calculated for three different periods of time when prostate cancer was diagnosed (1994–1997, 1998–2001 and 2002–2005), by age (15–59, 60–74, and 75–99), stage at diagnosis (I, II, III, IV, unknown) and place of residence (cities and towns or rural areas). Results. The survival of prostate cancer patients in Lithuania has dramatically increased. Five-year relative survival in the period 1994–1997 was 46.92% and in the period 2002–2005 it reached 86.49%. Medium age prostate cancer patients (60–74 years) compared to younger and older patients had better survival rates. Increasing survival was observed for all stages of disease. Lower five-year relative survival rate of prostate cancer patients was reported for men from villages or other rural areas compared to patients from cities and towns in all periods under study. Conclusions. The five-year survival rate of patients with prostate cancer has increased from 46.92% (95% CI 44.12–49.74) in 1994–1997 to 86.49% (95% CI 84.73–88.22) in 2002–2005 in Lithuania. The study identified survival differences by age and place of residence. Issues, such as access to care, quality of medical care, must be made equally available and accessible for the whole population with special attention to older men and men living in rural areas.

Survival in Adult Italian Cancer Patients, 1978–1989

1997 ◽  
Vol 83 (1) ◽  
pp. 39-425 ◽  
Author(s):  
Arduino Verdecchia ◽  
Arduino Verdecchia ◽  
Riccardo Capocaccia ◽  
Roberta De Angelis ◽  
Fulvia Valente ◽  
...  
Keyword(s):  
Cancer Patient ◽  
Cancer Patients ◽  
Patient Survival ◽  
National Level ◽  
International Comparisons ◽  
Relative Survival ◽  
Cancer Registries ◽  
Population Based ◽  
Cancer Site ◽  
Malignant Neoplasms

Aims To present a systematic analysis of population-based cancer patient survival in Italy. Methods Population-based survival data have been made available from 10 Italian cancer registries within the ITACARE project. Data, collected and validated using a common protocol, included over 100,000 patients with cancer diagnosed between 1978 and 1989. Multivariate weighted analysis was used to provide relative survival estimates attributable to Italy at national level. Results Results are presented, according to a systematic frame, as the main object of the ITACARE study, involving crude and relative survival figures for adult Italian cancer patients, by age, sex, period of diagnosis and registry area. An estimate with reference to Italy as a whole is also presented by cancer site and for all malignant neoplasms combined. Age-standardized relative survival figures are presented to allow comparisons between Italian registries and also to give a basis for international comparisons with countries involved in the EUROCARE study. Conclusions For the fist time, population-based survival of cancer patients is made available in Italy on a large scale analysis of data from all the Italian cancer registries in a combined action. Estimates of cancer patient survival at a national level in Italy allow proper international comparisons with European countries and give elements of evaluation and discussion on the performance of the Italian health care system.

DYNAMICS OF OBSERVED AND RELATIVE SURVIVAL OF COLON CANCER PATIENTS IN ST. PETERSBURG AND THE REPUBLIC OF BELARUS (ACCORDING TO POPULATION-BASED CANCER REGISTRIES)

2017 ◽  
Vol 63 (3) ◽  
pp. 394-405
Author(s):  
Vakhtang Merabishvili ◽  
Aleksey Okeanov ◽  
Alesya Yevmenenko
Keyword(s):  
Colon Cancer ◽  
Cancer Patients ◽  
Survival Rates ◽  
Cancer Control ◽  
Relative Survival ◽  
Cancer Registries ◽  
Population Based ◽  
Problem Analysis ◽  
The Republic ◽  
Analysis Of Dynamics

Actuality of problem. Analysis of observed and relative survival is related to important criteria for evaluation of cancer control at the population-based level covering all patients on the administrative territory as well as the group of treated patients. Comparison of the effectiveness of treatment of patients in different countries allows revealing more adequate methods of complex anti-cancer activities. In this paper such study was carried out with respect to colon cancer according to population-based cancer registries of the Republic of Belarus and St. Petersburg. Purpose of study is to compare dynamics of observed and relative survival rates in colon cancer patients in the Republic of Belarus and St. Petersburg. Materials and methods. In the basis of the study there were taken databases of population-based cancer registries of the Republic of Belarus and St. Petersburg and also there was used standard methodology by constructing expectancy tables and estimating the significance of differences in rates. Analysis of obtained data. There was performed in-depth comparative analysis of dynamics of survival rates by sex, age and histological tumor types. Conclusion. Conducted comparative study of survival colon cancer patients in the Republic of Belarus and St. Petersburg showed significant growth of rates however relative survival in Europe was much higher than in the Republic of Belarus and western regions of Russia.

Analyzing Survival Trends in Multiple Myeloma Patients in Pre and Post-Bortezomib Era Using the SEER Database

Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 2639-2639
Author(s):  
Jayadev Manikkam Umakanthan ◽  
Dipesh Uprety ◽  
Vineela Kasireddy
Keyword(s):  
Multiple Myeloma ◽  
Survival Rate ◽  
Survival Rates ◽  
Relative Survival ◽  
Population Based ◽  
P Value ◽  
Relative Standard Error ◽  
Population Based Study ◽  
Male And Female ◽  
Relative Standard

Abstract Background: Bortezomib is an antineoplastic agent that acts through protease inhibition. Since, its approval in 2003 by U.S. Food and Drug administration, it has been used religiously for multiple myeloma. There is no current population based study that assesses the survival benefit in multiple myeloma from bortezomib. We conducted a population based study to evaluate the relative survival rates in multiple myeloma patients in pre and post-Bortezomib era in the United States. Methods: We analyzed the Surveillance, Epidemiology, and End Results (SEER) 18 registry database to compare five-year relative survival rates (RS) among multiple myeloma patients. The study arms were categorized by gender (male and female), race (Caucasians and African-Americans) and age (20-59, ≥60 years). The RS were compared between pre-bortezomib era (1991-2002) and post-bortezomib era (2004-2011). The survival rate accompanied standard errors and the statistical significance was defined as p value <0.05. Results: The database comprised of 57,328 patients. The RS have improved significantly during post-bortezomib era in all cohorts under consideration. There was no significant difference in survival rate between male and female and between the African American and Caucasian. However, the relative survival was much better with the young adult (20-59 years) as compared to adult ≥60 years. The table detailing the relative survival is given below. Conclusion: The Primary treatment protocols for Multiple Myeloma have changed dramatically since the approval of Bortezomib in 2003. Other novel agents introduced in the last decade include thalidomide, Lenalidomide and liposomal doxorubicin that are used in conjunction with Bortezomib. Survival trends continue to improve and we believe this modest improvement in survival rate is mainly due to the introduction of Bortezomib and other novel agents. The next challenge is to find new drugs which would prevent relapses and further prolong survival. Abstract 2639. Table.Study armSubclass of cohortsPre-bortezomib era (1991-2002)Post- bortezomib era (2004-2011)Z scoreP ValueNRS (%)Relative Standard Error (SE) (%)NRS (%)Relative Standard Error (SE) (%) GenderMale13,06634.60.517,76546.10.615.904<0.0001Female11,58032.10.514,91743.70.614.765<0.0001 RaceCaucasian18,83632.90.423,98145.00.519.259<0.0001African American4,27434.70.86,39145.10.98.488<0.0001 Age group20-596,35848.10.69,43960.20.712.920<0.0001>=6018,28827.80.423,24338.40.516.606<0.0001 Total: male and female: 1991-2002; 24,646, RS 33.4%; SE 0.3%; 2004-2011; 32,682, RS 45.0%, SE 0.4%; Z score 21.766, P value <0.0001. Disclosures No relevant conflicts of interest to declare.

scholarly journals Ovarian cancer with pleural and lung metastasis in Dr. Soetomo Hospital, Surabaya, Indonesia, in 2014-2015

2018 ◽  
Vol 26 (1) ◽  
pp. 7
Author(s):  
Fitria Khusnul Khotimah ◽  
Anna Febriani ◽  
Pungky Mulawardhana
Keyword(s):  
Ovarian Cancer ◽  
Survival Rate ◽  
Cancer Patients ◽  
Median Survival ◽  
Lung Metastasis ◽  
Survival Rates ◽  
Secondary Data ◽  
Pleural Metastasis ◽  
Histopathological Type ◽  
Median Survival Rate

Objectives: To know the characteristics of ovarian cancer patients with pleural and lung metastasis, and survival rates of ovarian cancer patients with pleural and lung metastasis in Dr. Soetomo Hospital Surabaya in 2014-2015.Materials & Methods: This was a descriptive observational study using secondary data from medical records in dr. Soetomo Hospital, Surabaya, Indonesia, in 2014 and 2015Results: Number of new patients of ovarian cancer in dr. Soe-tomo, Hospital, Surabaya in 2014 was 170 patients (14%) and 122 patients (12%) in 2015. Ovarian cancer patients most often came at the stage IIIC (33.38%) with the most histopathological type was epithelial ovarian cancer. There were 5 patients with ovarian cancer with pleural metastasis and 7 patients with lung metastasis. Pleural metastasis was 80% diagnosed at the time of ovarian cancer’s diagnosis, whereas 57.15% of lung metastasis were diag-nosed >12 months after the ovarian cancer’s diagnosis. Pleural metastasis was established by pleural fluid cytology, while lung metastasis with radiological features and/or biopsies. The most common feature of lung metastasis was nodal (71.42%). Ascites was found in 80% of ovarian cancer with pleural metastasis, but only 42.86% in lung metastasis. In 2 patients receiving NAC chemotherapy and continued by interval debulking, both had negative residues. Median survival rate in ovarian cancer with pleural metastasis was 7 months, whereas in lung metastasis was 12 months.Conclusions: Number of new patients of ovarian cancer in 2014-2015 in dr. Soetomo Hospital was on rising and was the second largest number of visits after cervical cancer. In 2014-2015, there were 5 patients with ovarian cancer and pleural metastasis and 7 patients with ovarian cancer patients and lung metastasis. Median survival rate in ovarian cancer with pleural metastasis was 7 months, whereas in lung metastasis it was 12 months.

Carcinoids and High-Grade Neuroendocrine Carcinomas of the Ampulla of Vater: A Comparative Analysis of 139 Cases From the Surveillance, Epidemiology, and End Results Program—A Population Based Study

2010 ◽  
Vol 134 (11) ◽  
pp. 1692-1696 ◽  
Author(s):  
Jorge Albores-Saavedra ◽  
Alexandra Hart ◽  
Fredy Chablé-Montero ◽  
Donald E. Henson
Keyword(s):  
Survival Rates ◽  
Relative Survival ◽  
Large Cell ◽  
Ampulla Of Vater ◽  
Population Based ◽  
Carcinoid Tumors ◽  
Malignant Neoplasms ◽  
High Grade ◽  
Neuroendocrine Carcinomas ◽  
End Results

Abstract Context.—Neuroendocrine tumors of the ampulla of Vater constitute a heterogeneous group of neoplasms clinically and morphologically. Because they are rare, little is known about their demographics and biologic behavior. Objective.—To analyze the demographics and the 5- and 10-year relative survival rates of 139 patients with carcinoid tumors and high-grade neuroendocrine carcinomas of the ampulla. Design.—Using data from National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program from 1973 to 2006, we analyzed the demographics, morphology, and survival of patients with carcinoids and neuroendocrine carcinomas of the ampulla. Results.—SEER recorded 6081 cases of malignant neoplasms of the ampulla, of which 82 were carcinoid tumors and 57 were high-grade neuroendocrine carcinomas. Of these 57, 42 were neuroendocrine carcinomas, not otherwise specified; 9 were small cell carcinomas; and 6 were large cell neuroendocrine carcinomas. The incidence was higher in men than in women. Patients with carcinoid tumors were younger (mean age, 61.6 years) than those with high-grade neuroendocrine carcinomas (mean age, 67.5 years). Carcinoid tumors were smaller than high-grade neuroendocrine carcinomas. The frequency of lymph node metastasis was 28.5% for carcinoid tumors and 62% for high-grade neuroendocrine carcinomas. The 5- and 10-year relative survival rates of patients with carcinoid tumors were 82% and 71%, respectively. The 5- and 10-year relative survival rate of patients with high-grade neuroendocrine carcinomas was 15.7%. Conclusions.—Carcinoids of the ampulla of Vater are relatively rare. Carcinoids and high-grade neuroendocrine carcinomas of the ampulla are biologically and clinically similar to these tumors arising in other sites. Carcinoids were smaller and metastasized less frequently than high-grade neuroendocrine carcinomas.

Sign in / Sign up

Export Citation Format

Share Document